It’s only fair to share… Tisolagiline CAS 1894207-44-3 PCH79KLX33 (2S)-2-[[4-[4-(trifluoromethyl)phenyl]phenyl]methylamino]propanamide 322.32 g/mol SCHEME Tisolagiline (INNTooltip International Nonproprietary Name; developmental code names KDS-2010, SeReMABI) is a potent, highly selective, and reversible monoamine oxidase B (MAO-B) inhibitor which is under development for the treatment of Alzheimer’s disease and obesity.[1][2][3][4] It is taken by mouth.[1] Tisolagiline is being developed by NEUROBiOGEN and Scilex Bio.[1][2] As of December 2024, it is in phase 2 clinical trials for Alzheimer’s disease and …